<DOC>
	<DOCNO>NCT01929278</DOCNO>
	<brief_summary>Clindamycin 1.0 % - tretinoin 0.025 % gel ( CT Gel ) reformulation VELAC Gel contain active ingredient ( clindamycin 1.0 % tretinoin 0.025 % ) modify vehicle . This single-center , evaluator-blinded , randomize , placebo ( vehicle ) -controlled phase 1 study evaluate phototoxic potential CT Gel use 24 hour single application 3 set 3 study patch . The study expect enroll approximately 40 healthy adult volunteer . Each set study patch consist CT Gel patch , vehicle gel patch , blank patch ( contain CT Gel vehicle gel ) . After concurrent 24-hour single application 9 patch , 1 set patch ( set A ) remove , site irradiate 16 joules/cm2 ultraviolet A light ( UVA ) 0.75 minimal erythema dose ( MED ) UVA/ultraviolet B light ( UVB ) . The second set patch ( set B ) remove , site irradiate 16 joules/cm2 UVA , 0.75 MED UVB/UVA , follow 15 joules/cm2 visible light ( VIS ) . The third set patch ( set C ) remove , sit serve non irradiate control . Inflammatory response cutaneous effect score 1 hour patch removal follow-up visit 24 , 48 , 72 hour patch removal .</brief_summary>
	<brief_title>W0265-103 : A Single-Center , Evaluator-Blinded , Randomized , Placebo Controlled , Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0 % - Tretinoin 0.025 % Gel ( Ct Gel ) In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>1 . The capability understand provide sign dated write voluntary inform consent ( local national authorization requirement ) protocolspecific procedure perform . 2 . Male female subject age 18 65 year , inclusive , time consent . 3 . The ability complete study comply study instruction . 4 . Possessed Fitzpatrick skin type I ( always burn easily ; never tan ) , II ( always burn easily ; tan minimally ) , III ( burn moderately ; tan gradually ) would interfere read skin response . Determination skin type base sunburn tan history , well subject ' opinion response first 30 45 minute sun exposure . 5 . Sexually active female childbearing potential agree use medically acceptable method contraception receive protocolassigned product . A woman childbearing potential define one biologically capable become pregnant , include perimenopausal woman le 2 year last menses . Acceptable contraceptive method include follow : Hormonal contraception , include oral , injectable , implantable method start least 2 month prior screen . If hormonal contraception start less 2 month prior screen , form nonhormonal contraception add third continuous month hormonal contraception complete . Two form non hormonal contraception , include intrauterine device properly use barrier method ( eg , male female condom , diaphragm , cervical cap ) . Subjects surgical sterilization , include tubal ligation partner 's vasectomy , use form nonhormonal contraception . A barrier method sterilization plus spermatocide acceptable . Women currently sexually active lactate agree use medically accept method contraception become sexually active participate study . 1 . Currently diagnose cancer previous history cancer , include skin cancer , severe photodamaged skin . Severe photodamaged skin characterize yellowgray color , wrinkle visible normal skin , prior skin malignancy . 2 . Female subject pregnant , attempt become pregnant , breast feeding . 3 . Received investigational drug within 4 week study day 1 schedule receive investigational drug study product study . 4 . Used contraindicated prescription drug within 4 week 5 halflives , whichever longer , first dose study product , unless agree clinically relevant principal investigator project physician . 5 . Participated previous study study product . 6 . Current use medication , opinion investigator , may affect evaluation study product place subject undue risk . 7 . Suffered disease condition , opinion investigator , may affect evaluation study product place subject undue risk . 8 . Any major illness within 30 day screen examination . 9 . Considered immunocompromised use immunosuppressant drug . 10 . Clinically relevant history current evidence abuse alcohol drug . 11 . History know suspect intolerance ingredient study product ( ie , test comparator product ) , hypoallergenic tape , cotton patch . 12 . Clinically relevant history presence respiratory ( include chronic asthma require repetitive drug intervention ) , gastrointestinal , renal , hepatic , hematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . 13 . Considered unable unlikely attend necessary visit . 14 . History severe reaction exposure sunlight , include previous experience photoallergy , solar urticaria , polymorphous light eruption , photo exacerbate systemic disease . 15 . Current use expect use photosensitize medication ( overthecounter prescription ) , herbal supplement , use know photosensitize material . 16 . Clinically significant skin disease contraindicate participation interfere test site evaluation , include psoriasis , eczema , atopic dermatitis , acne , dysplastic nevus , skin pathology . 17 . Investigator inability evaluate skin around potential test site due sunburn , unevenness skin tone , tattoo , scar , excessive hair , freckle , birthmark , mole , skin abnormality . 18 . Used topical medication ( eg , corticosteroid immunosuppressive ) potential test site within last 7 day prior screen visit 1 . 19 . Currently receive allergy injection , due receive injection , within 7 day prior screen visit 1 , expect begin injection study participation . 20 . Used antihistamine prescription anti inflammatory drug within 72 hour day 1 visit . Permitted exception acetaminophen recommend dos aspirin dos â‰¤81 mg/day . 21 . Participated patch test study irritation sensitization test involve ultraviolet exposure within last 4 week . 22 . Employees Hill Top Research Stiefel Laboratories involve study , immediate family member ( partner , offspring , parent , sibling , sibling 's offspring ) employee involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>